Onasemnogene abeparvovec for treating spinal muscular atrophy

Equality Impact Assessment (Guidance development) (PDF 160 KB)

Register of interests (MSWord 39 KB)

Final evaluation determination

Committee papers (PDF 134 KB)

Committee papers Managed Access Agreement (PDF 143 KB)

Public committee slides (PDF 393 KB)

Final evaluation determination document (PDF 430 KB)

Evaluation consultation

Public committee slides October 2020 & February 2021 (PDF 1.24 MB)

Committee papers (PDF 6.72 MB)

Evaluation consultation document (PDF 444 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 767 KB)

Equality impact assessment (Scoping) (PDF 127 KB)

Final scope (PDF 190 KB)

Final stakeholder list (PDF 207 KB)

Draft scope pre referral (PDF 316 KB)

Draft matrix pre referral (PDF 295 KB)